This study found that one-time universal HDV testing among HBsAg-positive persons and treatment of an estimated 50% of persons with chronic HDV with elevated ALT or compensated cirrhosis with PEG-IFN in the US cost $22 333/QALY. This evidence concerns the gene GPT and Cirrhosis.